Effectiveness and Safety of Adjuvant Software Based on Virtual Reality for Post-thoracoscopic Surgery Pain
Launched by GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL · Aug 25, 2024
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating whether using virtual reality (VR) software can help reduce pain after patients have undergone video-assisted thoracoscopic surgery, which is a type of minimally invasive surgery on the chest. The study is currently recruiting participants who are at least 18 years old and have had surgery within the last day. Eligible participants should be comfortable using smartphones and the internet, and they should be experiencing moderate to severe pain after their surgery.
If you decide to participate, you'll be asked to use the VR software in addition to your usual pain management treatment. The research team wants to see if this new approach can make a difference in how well you manage your pain. It's important to note that individuals with certain conditions, like severe cognitive impairment or those who can't comfortably use VR due to vision or motion issues, won't be included in the study. Overall, this trial aims to explore an innovative way to improve comfort and recovery for patients after surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1.Age greater than or equal to 18 years.
- • 2.Patients within 1 day after thoracoscopic surgery.
- • 3.Junior high school degree or above, Mandarin communication is unimpeded, with certain Internet knowledge and mobile phone reading and writing skills.
- • 4.The score of the numeric grading scale (NRS) at 24 hours postoperatively ≥ 4 points.
- • 5.Patients who are able to understand the purpose of the study, voluntarily participate in and sign the informed consent form, and are willing to complete the follow-up as required by the protocol.
- Exclusion Criteria:
- • 1.Patients with severe cognitive impairment.
- • 2.Patients with a previous diagnosis of epilepsy, dementia, migraine, or other neurological disease that may result in the inability to use postoperative analgesic adjuvant therapy software or that may have adverse effects.
- • 3.Patients who are unable to understand or speak Mandarin.
- • 4.Patients who have visual abnormalities, severe hearing impairment, or motion sickness, etc., and are unable to view VR.
- • 5.Patients with trauma to the eyes, face, or neck that prevents the comfortable use of the VR device.
- • 6.Patients with severe heart, liver, kidney, hematologic, digestive, nervous system diseases and malnutrition.
- • 7.Patients who have previously used virtual reality software for pain that has not responded to treatment.
- • 8.Patients with a history of severe alcohol abuse, long-term heavy drinking, and symptoms of alcohol dependence.
- • 9.Patients who have participated in any analgesic interventional study within the past 1 week.
- • 10.Females who are pregnant or plan to become pregnant during the study.
- • 11.The patient or their immediate family member works for a digital health or pharmaceutical company for acute or chronic pain treatment.
- • 12.Patients who are unable to use electronic devices such as smartphones.
- • 13.Other conditions that the investigator considers inappropriate for participation in a clinical trial.
About Guangdong Provincial People's Hospital
Guangdong Provincial People's Hospital is a leading tertiary healthcare institution located in Guangdong Province, China, renowned for its comprehensive medical services and advanced research capabilities. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical science through innovative research and the rigorous evaluation of new therapies and interventions. With a multidisciplinary team of experienced clinicians and researchers, the institution prioritizes patient safety and ethical standards while fostering collaborations with academic and industry partners to enhance healthcare outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tianjin, Tianjin, China
Maoming, Guangdong, China
Guangzhou, Guangdong, China
Shanghai, Shanghai, China
Patients applied
Trial Officials
Wen-Zhao Zhong
Principal Investigator
Guangdong Provincial People's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported